{
    "clinical_study": {
        "@rank": "163001", 
        "acronym": "68-DOTANOC-GEP", 
        "brief_summary": {
            "textblock": "Evaluation of the  diagnostic performance of PET / CT with 68Ga-DOTANOC in\n      Gastroenteropancreatic Neuroendocrine Tumors with comparison with other techniques used in\n      routine clinical practice (octreoscan \u00ae  ; multiphase SPECT / CT, MRI or endoscopy).\n\n      Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed.  Expected\n      results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy\n      octreoscan \u00ae, with a potential impact on the therapeutic management of patients."
        }, 
        "brief_title": "TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients With Gastroenteropancreatic Neuroendocrine Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Neuroendocrine Tumors", 
                "Intestinal Neoplasms", 
                "Pancreatic Neoplasms", 
                "Stomach Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age over 18 years\n\n          -  effective contraception or exclusion of pregnancy dosage of beta-HCG in women of\n             childbearing age\n\n          -  Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional\n             imaging (multiphase CT; MRI, US endoscopy) associated or not associated  with\n             clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR\n\n          -  Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the\n             initial staging OR\n\n          -  Suspicion of recurrence or progression of well differentiated TE-GEP tumors on\n             conventional imaging or laboratory tests (increase in tumor markers) OR\n\n          -  Clinical or biological syndrome strongly suggestive of digestive endocrine disease\n             without identification of lesions with conventional imaging\n\n          -  Informed consent and patient's written\n\n          -  Affiliation to an insurance\n\n        Exclusion Criteria:\n\n          -  Multiple endocrine neoplasia\n\n          -  TE GEP tumor not differentiated\n\n          -  Pregnancy and lactation\n\n          -  Persons protected by law\n\n          -  Restlessness, inability to lie still hold at least 1 hour; Claustrophobia\n\n          -  Poor compliance predictable or inability to undergo medical test for geographical,\n             social or psychological\n\n          -  Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks\n             of previous morphological and scintigraphic examinations. In case of treatment with\n             somatostatin analogues delayed, scans will be performed 4 weeks after the last\n             injection. However, a shorter period may be observed to avoid to do again the initial\n             assessment exams.\n\n          -  malignancy except basal cell cancers and cancer in situ of the cervix\n\n          -  Contraindication of  injection of a contrast agent necessary for the production of\n             multiphase scanner.\n\n          -  Patients who had a CT scan without injection of contrast material can not participate\n             in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747096", 
            "org_study_id": "BRD 11/5-K"
        }, 
        "intervention": {
            "intervention_name": "68-Ga-DOTANOC", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gastroenteropancreatic Neuroendocrine Tumors", 
            "immuno PET (iPET)", 
            "Gallium (68-Ga)", 
            "DOTANOC"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Olivier Couturier <ocouturier70@me.com>", 
                    "last_name": "Oliiver Couturier, PhD, MD"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
                    "phone": "0032253482840"
                }, 
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49100"
                    }, 
                    "name": "Angers Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Olivier Couturier, PhD, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Vincent Rohmer, PU, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Olivier Morel, MD"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
                    "phone": "0032253482840"
                }, 
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49100"
                    }, 
                    "name": "Insitutut de Canc\u00e9rologie de l'Ouest, Ren\u00e9 Papin"
                }, 
                "investigator": {
                    "last_name": "Oliver Morel, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Clichy", 
                        "country": "France", 
                        "zip": "92110"
                    }, 
                    "name": "H\u00f4pital Beaujon"
                }, 
                "investigator": {
                    "last_name": "Rachida Labtahi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75018"
                    }, 
                    "name": "H\u00f4pital Bichat"
                }, 
                "investigator": {
                    "last_name": "Dominique Leguludec, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Rousseau Caroline <Caroline.Rousseau@ico.unicancer.fr>", 
                    "last_name": "Caroline Rousseau, PhD, MD", 
                    "phone": "0032240679931"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
                    "phone": "0032253482840"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de l'Ouest, Ren\u00e9 Gauducheau"
                }, 
                "investigator": {
                    "last_name": "Caroline Rousseau, PhD, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "catherine.ansquer@chu-nantes.fr", 
                    "last_name": "Catherine Ansquer, MD", 
                    "phone": "0032240084136"
                }, 
                "contact_backup": {
                    "email": "evelyne.cerato@chu-nantes.fr", 
                    "last_name": "Evelyne Scotet-C\u00e9rato, PhD,", 
                    "phone": "0032253482840"
                }, 
                "facility": {
                    "address": {
                        "city": "Saint Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Nantes Hospital"
                }, 
                "investigator": {
                    "last_name": "Catherine Ansquer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "official_title": "Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octr\u00e9oscan \u00ae Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors", 
        "other_outcome": [
            {
                "measure": "Assess the clinical impact of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Assess the relevance of decisions of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Assess  the value of PET / CT 68 Ga-DOTANOC in terms of specificity and predictive value for the detection of locations of GEP.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "the vital signs and clinical  tolerance will be assess during the 2 hours following injection of the radiopharmaceutical.", 
                "measure": "Tolerance of 68-Ga-DOTANOC", 
                "safety_issue": "Yes", 
                "time_frame": "12 mois"
            }
        ], 
        "overall_contact": {
            "email": "catherine.ansquer@chu-nantes.fr", 
            "last_name": "Catherine Ansquer, MD", 
            "phone": "0032 2 40 08 4136"
        }, 
        "overall_contact_backup": {
            "email": "evelyne.cerato@chu-nantes.fr", 
            "last_name": "Evelyne Scotet-C\u00e9rato, PhD", 
            "phone": "00 32 253482840"
        }, 
        "overall_official": {
            "affiliation": "Nantes Hospital", 
            "last_name": "Catherine Ansquer, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reference to the gold standard (that will be obtained from the data of histology and / or follow-up imaging at least 12 months", 
            "measure": "Detection of Gastroenteropancreatic Neuroendocrine Tumors  lesions in the initial assessment or during the search of recurrence.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Compare the diagnostic performance of PET / CT with 68Ga-DOTANOC with the standard process", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}